Clear Filter

Apr 13, 2022

AbbVie Celebrates 30th Anniversary of CF Scholarship with Opening of Application Period for Students with Cystic Fibrosis

NORTH CHICAGO, Ill., April 13, 2022 /PRNewswire/ -- AbbVie today announced that the AbbVie Cystic Fibrosis (CF) Scholarship program is now accepting applications for the 2022-2023 academic school year. This year's program marks 30 years of honoring and supporting young adults with CF as they pursue their educational dreams. Eligible undergraduate and graduate students are invited to apply for the scholarship until May 25, 2022, at 11:00 a.m. U.S. Eastern Time by visiting Students can apply online or by downloading an application on the official scholarship website.

Apr 13, 2022

BOTOX® Cosmetic (onabotulinumtoxinA) Celebrates 20 Years Since First U.S. FDA Approval

Iconic Brand Was The First Product Of Its Kind To Receive U.S. Food And Drug Administration Approval In 2002 For Aesthetic Use And Is Honoring This Milestone By Celebrating Its Loyal Patients And Providers

Apr 12, 2022

AbbVie Presents Positive Investigational Navitoclax Combination Data in Phase 2 REFINE Study Suggesting Anti-Fibrosis Activity for Patients with Myelofibrosis

NORTH CHICAGO, Ill., April 12, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new data from a Phase 2 trial of navitoclax in combination with ruxolitinib in patients with myelofibrosis. The results were presented at the American Association for Cancer Research annual meeting (AACR 2022, abstract #LB108). Navitoclax is an investigational, first-in-class, oral BCL-XL/BCL-2 inhibitor that is designed to activate programmed cell death (apoptosis) in cancer cells. Navitoclax and its safety and efficacy are under evaluation as part of ongoing Phase 2 and registrational Phase 3 studies.

Apr 05, 2022

Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY™ (pilocarpine HCI ophthalmic solution) 1.25% in Adults with Age-Related Blurry Near Vision (Presbyopia)

NORTH CHICAGO, Ill., April 5, 2022 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV) company, today announced that the Phase 3 VIRGO trial evaluating the safety and efficacy of investigational twice-daily administration of VUITY™ (pilocarpine HCl ophthalmic solution) 1.25% in adults with presbyopia met its primary efficacy endpoint, improving near vision without compromising distance vision at Hour 9 (3 hours after the second drop) on Day 14. Additional details of this trial will be presented at future medical congresses and will serve as the basis for a supplemental New Drug Application submission for an optional twice-daily administration to the U.S. Food and Drug Administration (FDA) in the second quarter of 2022. Approved by the FDA in October 2021 for once-daily use, VUITY is the first and only eye drop to treat age-related blurry near vision in adults.

Mar 29, 2022

AbbVie to Showcase Breadth of Neuroscience Portfolio and Pipeline at American Academy of Neurology (AAN) 2022 Annual Meeting

-- AbbVie to present 30 abstracts demonstrating its leadership in neuroscience, including continued migraine treatment research across the spectrum of the disease, commitment to patients with advanced Parkinson's disease, and new studies in spasticity and cervical dystonia

Mar 29, 2022

Allergan Aesthetics Brings Data, Innovation & Industry Expertise to the 2022 Aesthetic and Anti-aging Medicine World Congress (AMWC)

IRVINE, Calif., March 29, 2022 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, will join industry colleagues and healthcare providers from around the globe for the 20th edition of AMWC in Monaco, France.

Mar 21, 2022

AbbVie and Allergan Aesthetics to Present New Research Across Dermatology Portfolio at 2022 AAD Annual Meeting

NORTH CHICAGO, Ill., March 21, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Allergan Aesthetics, an AbbVie company, today announced they will present 12 abstracts and two late-breaking presentations during the 2022 American Academy of Dermatology (AAD) Annual Meeting, March 25-29, in Boston. Data across AbbVie and Allergan's diversified portfolio of medical and aesthetic dermatology products underscore the companies' deep-rooted commitment to advancing science and striving to redefine the standards of patient care.

Mar 16, 2022

RINVOQ® (upadacitinib) Receives FDA Approval for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

NORTH CHICAGO, Ill., March 16, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib) for the treatment of adults with moderately to severely active ulcerative colitis (UC) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers. This FDA approval is the first indication for RINVOQ in gastroenterology and is supported by efficacy and safety data from three Phase 3 randomized, double-blind, placebo-controlled clinical studies.

Mar 15, 2022

Now Available Over the Counter, LASTACAFT® Provides Eye Allergy Itch Relief in Minutes that Lasts Through 16 Hours

-          Itchy allergy eyes affect an estimated 40% of Americans1

Mar 15, 2022

AbbVie and Scripps Research Announce Collaboration to Develop Antiviral Treatments for COVID-19

NORTH CHICAGO, Ill., March 15, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Scripps Research, an independent, non-profit biomedical research and drug discovery institute, today announced a global collaboration to develop potential novel, direct-acting antiviral treatments for COVID-19.